We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice.
- Authors
Warimwe, George M.; Lorenzo, Gema; Lopez-Gil, Elena; Reyes-Sandoval, Arturo; Cottingham, Matthew G.; Spencer, Alexandra J.; Collins, Katharine A.; Dicks, Matthew D.J.; Milicic, Anita; Lall, Amar; Furze, Julie; Turner, Alison V.; Hill, Adrian V.S.; Brun, Alejandro; Gilbert, Sarah C.
- Abstract
Background Rift Valley Fever (RVF) is a viral zoonosis that historically affects livestock production and human health in sub-Saharan Africa, though epizootics have also occurred in the Arabian Peninsula. Whilst an effective live-attenuated vaccine is available for livestock, there is currently no licensed human RVF vaccine. Replication-deficient chimpanzee adenovirus (ChAd) vectors are an ideal platform for development of a human RVF vaccine, given the low prevalence of neutralizing antibodies against them in the human population, and their excellent safety and immunogenicity profile in human clinical trials of vaccines against a wide range of pathogens. Methods Here, in BALB/c mice, we evaluated the immunogenicity and efficacy of a replicationdeficient chimpanzee adenovirus vector, ChAdOx1, encoding the RVF virus envelope glycoproteins, Gn and Gc, which are targets of virus neutralizing antibodies. The ChAdOx1- GnGc vaccine was assessed in comparison to a replication-deficient human adenovirus type 5 vector encoding Gn and Gc (HAdV5-GnGc), a strategy previously shown to confer protective immunity against RVF in mice. Results A single immunization with either of the vaccines conferred protection against RVF virus challenge eight weeks post-immunization. Both vaccines elicited RVF virus neutralizing antibody and a robust CD8+ T cell response. Conclusions Together the results support further development of RVF vaccines based on replicationdeficient adenovirus vectors, with ChAdOx1-GnGc being a potential candidate for use in future human clinical trials.
- Subjects
SUB-Saharan Africa; RIFT Valley fever; ARBOVIRUS diseases; VACCINATION; VIRAL hepatitis
- Publication
Virology Journal, 2013, Vol 10, Issue 1, p1
- ISSN
1743-422X
- Publication type
Article
- DOI
10.1186/1743-422X-10-349